| Unbound MEDLINE results for: | Bookmark this site | | Articles related to 11577258 [Unique ID], provided by the PubMed system | |
| |
|
| | 1 - 10 of 677 journal articles in the PubMed database | Email to a friend | | |
| Kimmelstiel C, Phang R, Rehman A, et al.
Short-term comparative outcomes associated with the use of GP IIb/IIIa antagonists in patients undergoing coronary intervention. [Journal Article]
J Thromb Thrombolysis 2001 May; 11(3):203-9.
Abstract | Full Citation | Publisher Full Text | Find Related Articles | | Lincoff AM, Bittl JA, Harrington RA, et al.
Bivalirudin and provisional glycoprotein IIb/IIIa blockade compared with heparin and planned glycoprotein IIb/IIIa blockade during percutaneous coronary intervention: REPLACE-2 randomized trial. [Clinical Trial, Journal Article, Multicenter Study, Randomized Controlled Trial]
JAMA 2003 Feb 19; 289(7):853-63.
Abstract | Full Citation | Publisher Full Text | Find Related Articles | | McCollam PL, Foster DA, Riesmeyer JS
Cost and effectiveness of glycoprotein IIb/IIIa-receptor inhibitors in patients with acute myocardial infarction undergoing percutaneous coronary intervention. [Journal Article]
Am J Health Syst Pharm 2003 Jun 15; 60(12):1251-6.
Abstract | Full Citation | Publisher Full Text | Find Related Articles | | Ferguson JJ, Antman EM, Bates ER, et al.
Combining enoxaparin and glycoprotein IIb/IIIa antagonists for the treatment of acute coronary syndromes: final results of the National Investigators Collaborating on Enoxaparin-3 (NICE-3) study. [Clinical Trial, Journal Article, Multicenter Study]
Am Heart J 2003 Oct; 146(4):628-34.
Abstract | Full Citation | Publisher Full Text | Find Related Articles | |
Comparative 30-day economic and clinical outcomes of platelet glycoprotein IIb/IIIa inhibitor use during elective percutaneous coronary intervention: Prairie ReoPro versus Integrilin Cost Evaluation (PRICE) Trial. [Clinical Trial, Journal Article, Multicenter Study, Randomized Controlled Trial]
Am Heart J 2001 Mar; 141(3):402-9.
Abstract | Full Citation | Publisher Full Text | Find Related Articles | | Lincoff AM, Tcheng JE, Califf RM, et al.
Sustained suppression of ischemic complications of coronary intervention by platelet GP IIb/IIIa blockade with abciximab: one-year outcome in the EPILOG trial.Evaluation in PTCA to Improve Long-term Outcome with abciximab GP IIb/IIIa blockade. [Clinical Trial, Journal Article, Randomized Controlled Trial]
Circulation 1999 Apr 20; 99(15):1951-8.
Abstract | Full Citation | Publisher Full Text | Find Related Articles | | Dyke CM
Safety of glycoprotein IIb-IIIa inhibitors: A heart surgeon's perspective. [Journal Article, Review]
Am Heart J 1999 Oct; 138(4 Pt 2):307-16.
Abstract | Full Citation | Publisher Full Text | Find Related Articles | | Coons JC, Seybert AL, Saul MI, et al.
Outcomes and costs of abciximab versus eptifibatide for percutaneous coronary intervention. [Journal Article]
Ann Pharmacother 2005 Oct; 39(10):1621-6.
Abstract | Full Citation | Publisher Full Text | Find Related Articles | | Gruberg L, Suleiman M, Kapeliovich M, et al.
Glycoprotein IIb/IIIa inhibitors during rescue percutaneous coronary intervention in acute myocardial infarction. [Journal Article]
J Invasive Cardiol 2006 Feb; 18(2):59-62.
Abstract | Full Citation | Publisher Full Text | Find Related Articles |   |
|
| |
Advertise on this site.
|
